Scandion Oncology A/S (SCOL.ST)
SEK 0.08
(-6.78%)
SEK 0.08
(-6.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.43 Million DKK | -81.98% |
| 2022 | 19.07 Million DKK | 63.33% |
| 2021 | 11.67 Million DKK | -61.77% |
| 2020 | 30.54 Million DKK | 1852.47% |
| 2019 | 1.56 Million DKK | 57.59% |
| 2018 | 992.64 Thousand DKK | 95.01% |
| 2017 | 509.01 Thousand DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.26 Million DKK | 167.92% |
| 2024 Q1 | 3.08 Million DKK | -10.33% |
| 2023 Q2 | 7.92 Million DKK | -38.29% |
| 2023 Q3 | 8.72 Million DKK | 10.09% |
| 2023 FY | 3.43 Million DKK | -81.98% |
| 2023 Q1 | 12.83 Million DKK | -32.71% |
| 2023 Q4 | 3.43 Million DKK | -60.57% |
| 2022 Q2 | 19.95 Million DKK | 108.19% |
| 2022 FY | 19.07 Million DKK | 63.33% |
| 2022 Q4 | 19.07 Million DKK | -8.58% |
| 2022 Q3 | 20.86 Million DKK | 4.53% |
| 2022 Q1 | 9.58 Million DKK | -17.91% |
| 2021 Q4 | 11.67 Million DKK | 13.47% |
| 2021 Q2 | 9.99 Million DKK | 47.38% |
| 2021 Q1 | 6.78 Million DKK | -77.8% |
| 2021 FY | 11.67 Million DKK | -61.77% |
| 2021 Q3 | 10.29 Million DKK | 2.98% |
| 2020 Q2 | 2.77 Million DKK | 57.87% |
| 2020 Q3 | 4.07 Million DKK | 46.55% |
| 2020 FY | 30.54 Million DKK | 1852.47% |
| 2020 Q4 | 30.54 Million DKK | 650.25% |
| 2020 Q1 | 1.75 Million DKK | 12.48% |
| 2019 Q3 | 1.97 Million DKK | 85.43% |
| 2019 Q2 | 1.06 Million DKK | 16.08% |
| 2019 Q1 | 915.69 Thousand DKK | -7.75% |
| 2019 Q4 | 1.56 Million DKK | -20.63% |
| 2019 FY | 1.56 Million DKK | 57.59% |
| 2018 Q2 | 1.8 Million DKK | 0.0% |
| 2018 Q3 | 3.27 Million DKK | 81.46% |
| 2018 Q4 | 992.64 Thousand DKK | -69.7% |
| 2018 FY | 992.64 Thousand DKK | 95.01% |
| 2017 Q4 | 509.01 Thousand DKK | 0.0% |
| 2017 FY | 509.01 Thousand DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Lipum AB (publ) | 7.53 Million SEK | 54.391% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 96.775% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -45.74% |
| BioArctic AB (publ) | 139.5 Million SEK | 97.536% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 90.064% |
| Mendus AB (publ) | 51.22 Million SEK | 93.288% |
| Intervacc AB (publ) | 21.68 Million SEK | 84.142% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 87.127% |
| Active Biotech AB (publ) | 13.4 Million SEK | 74.343% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 97.227% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 78.668% |
| Aptahem AB (publ) | 8.99 Million SEK | 61.791% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 91.586% |
| Kancera AB (publ) | 17.97 Million SEK | 80.877% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 92.555% |
| Fluicell AB (publ) | 8.91 Million SEK | 61.436% |
| Saniona AB (publ) | 86.08 Million SEK | 96.006% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 33.346% |
| Biovica International AB (publ) | 34.76 Million SEK | 90.111% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 70.535% |
| AcouSort AB (publ) | 10.37 Million SEK | 66.872% |
| Xintela AB (publ) | 14.01 Million SEK | 75.469% |
| Ziccum AB (publ) | 6.38 Million SEK | 46.18% |
| Genovis AB (publ.) | 98.04 Million SEK | 96.494% |
| Abliva AB (publ) | 16.78 Million SEK | 79.513% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.398% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 70.283% |
| OncoZenge AB (publ) | 1.69 Million SEK | -102.354% |
| CombiGene AB (publ) | 4.15 Million SEK | 17.276% |
| Camurus AB (publ) | 414.81 Million SEK | 99.171% |
| Corline Biomedical AB | 6.78 Million SEK | 49.359% |
| Amniotics AB (publ) | 10.54 Million SEK | 67.403% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 94.397% |
| 2cureX AB (publ) | 2.93 Million SEK | -17.138% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 22.323% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.78% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 95.215% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 75.036% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 82.06% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 33.82% |
| I-Tech AB | 16.2 Million SEK | 78.784% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.71% |
| Cyxone AB (publ) | 4.69 Million SEK | 26.758% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 74.205% |
| Biosergen AB | 5.08 Million SEK | 32.389% |
| Cantargia AB (publ) | 54.97 Million SEK | 93.746% |
| NextCell Pharma AB | 13.68 Million SEK | 74.885% |
| Nanologica AB (publ) | 79.32 Million SEK | 95.666% |
| SynAct Pharma AB | 51.83 Million SEK | 93.367% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 56.749% |
| LIDDS AB (publ) | 3.75 Million SEK | 8.466% |
| BioInvent International AB (publ) | 90.45 Million SEK | 96.199% |
| Alzinova AB (publ) | 9.33 Million SEK | 63.155% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 98.107% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 81.41% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -91.639% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 10.422% |
| Simris Alg AB (publ) | 148.93 Million SEK | 97.692% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 95.166% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.287% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 73.023% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 52.645% |